FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145273349> ?p ?o ?g. }

• W2145273349 endingPage "1588" @default.
• W2145273349 startingPage "1581" @default.
• W2145273349 abstract "Objective. To evaluate the clinical response to and safety of single and repeat doses of a chimeric anti-CD4 monoclonal antibody, cM-T412, in patients with rheumatoid arthritis (RA) concomitantly treated with a stable regimen of low-dose methotrexate. Methods. Sixty-four patients with refractory RA, who were already receiving stable doses of methotrexate, were randomized into a multicenter, double-blind, placebo-controlled trial to receive 3 monthly treatments with either a placebo, or 5, 10, or 50 mg cM-T412, given intravenously. Results. Using ≥50% improvement in swollen joint counts as a criterion for clinical response, 13%, 13%, 18%, and 13% of patients receiving 50, 10, or 5 mg cM-T412, or the placebo, respectively, exhibited a clinical response at 3 months of therapy. Using ≥50% improvement in tender joint counts as a measure of clinical efficacy at 3 months, 19%, 13%, 12%, and 6% of patients receiving 50, 10, or 5 mg cM-T412, or the placebo, respectively, exhibited a clinical response. “Flu-like” symptoms (fever, chills, rigor) within 24 hours of the infusion occurred more frequently in the groups receiving 50-mg (29%) and 10-mg (31%) doses of cM-T412 than those receiving 5 mg cM-T412 (12%) or the placebo (13%). Significant CD4+ T cell depletion occurred in the 50-mg group (mean of 353 CD4+ T cells/mm3 at 6 months versus 856 CD4+ T cells/mm3 at baseline). All patients were followed up for 12 months after the final treatment; no opportunistic infectious complications occurred. Conclusion. Treatment with cM-T412 in this cohort of RA patients who were also taking methotrexate was not associated with clinical efficacy or enhanced toxicity from infectious complications, despite significant peripheral CD4+ T cell depletion." @default.
• W2145273349 created "2016-06-24" @default.
• W2145273349 creator A5004856138 @default.
• W2145273349 creator A5014323914 @default.
• W2145273349 creator A5023973423 @default.
• W2145273349 creator A5025358988 @default.
• W2145273349 creator A5026240805 @default.
• W2145273349 creator A5030335777 @default.
• W2145273349 creator A5033838025 @default.
• W2145273349 creator A5046442782 @default.
• W2145273349 creator A5064599465 @default.
• W2145273349 creator A5066780563 @default.
• W2145273349 creator A5070870936 @default.
• W2145273349 date "1995-11-01" @default.
• W2145273349 modified "2023-10-16" @default.
• W2145273349 title "Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-cd4 antibody, cm-t412, in rheumatoid arthritis patients receiving concomitant methotrexate" @default.
• W2145273349 cites W127077327 @default.
• W2145273349 cites W1977024519 @default.
• W2145273349 cites W1986778299 @default.
• W2145273349 cites W1987378608 @default.
• W2145273349 cites W1987930131 @default.
• W2145273349 cites W1993662593 @default.
• W2145273349 cites W2000417322 @default.
• W2145273349 cites W2001070192 @default.
• W2145273349 cites W2003169520 @default.
• W2145273349 cites W2003913420 @default.
• W2145273349 cites W2004328907 @default.
• W2145273349 cites W2015865604 @default.
• W2145273349 cites W2017290479 @default.
• W2145273349 cites W2040505385 @default.
• W2145273349 cites W2042818781 @default.
• W2145273349 cites W2044412629 @default.
• W2145273349 cites W2045509256 @default.
• W2145273349 cites W2050641852 @default.
• W2145273349 cites W2065019144 @default.
• W2145273349 cites W2081935520 @default.
• W2145273349 cites W2083856101 @default.
• W2145273349 cites W2088158803 @default.
• W2145273349 cites W2091943129 @default.
• W2145273349 cites W2093599503 @default.
• W2145273349 cites W2095029406 @default.
• W2145273349 cites W2095188728 @default.
• W2145273349 cites W2103709037 @default.
• W2145273349 cites W2103825824 @default.
• W2145273349 cites W2108238886 @default.
• W2145273349 cites W2108891346 @default.
• W2145273349 cites W2116594823 @default.
• W2145273349 cites W2131840622 @default.
• W2145273349 cites W2143053368 @default.
• W2145273349 cites W2151246967 @default.
• W2145273349 cites W2152348310 @default.
• W2145273349 cites W2317283438 @default.
• W2145273349 cites W2337516302 @default.
• W2145273349 cites W2464177776 @default.
• W2145273349 cites W4301967193 @default.
• W2145273349 doi "https://doi.org/10.1002/art.1780381109" @default.
• W2145273349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7488278" @default.
• W2145273349 hasPublicationYear "1995" @default.
• W2145273349 type Work @default.
• W2145273349 sameAs 2145273349 @default.
• W2145273349 citedByCount "105" @default.
• W2145273349 countsByYear W21452733492012 @default.
• W2145273349 countsByYear W21452733492013 @default.
• W2145273349 countsByYear W21452733492014 @default.
• W2145273349 countsByYear W21452733492015 @default.
• W2145273349 countsByYear W21452733492016 @default.
• W2145273349 countsByYear W21452733492018 @default.
• W2145273349 countsByYear W21452733492020 @default.
• W2145273349 countsByYear W21452733492021 @default.
• W2145273349 countsByYear W21452733492023 @default.
• W2145273349 crossrefType "journal-article" @default.
• W2145273349 hasAuthorship W2145273349A5004856138 @default.
• W2145273349 hasAuthorship W2145273349A5014323914 @default.
• W2145273349 hasAuthorship W2145273349A5023973423 @default.
• W2145273349 hasAuthorship W2145273349A5025358988 @default.
• W2145273349 hasAuthorship W2145273349A5026240805 @default.
• W2145273349 hasAuthorship W2145273349A5030335777 @default.
• W2145273349 hasAuthorship W2145273349A5033838025 @default.
• W2145273349 hasAuthorship W2145273349A5046442782 @default.
• W2145273349 hasAuthorship W2145273349A5064599465 @default.
• W2145273349 hasAuthorship W2145273349A5066780563 @default.
• W2145273349 hasAuthorship W2145273349A5070870936 @default.
• W2145273349 hasConcept C121332964 @default.
• W2145273349 hasConcept C126322002 @default.
• W2145273349 hasConcept C141071460 @default.
• W2145273349 hasConcept C142424586 @default.
• W2145273349 hasConcept C142724271 @default.
• W2145273349 hasConcept C204787440 @default.
• W2145273349 hasConcept C27081682 @default.
• W2145273349 hasConcept C2777077863 @default.
• W2145273349 hasConcept C2777575956 @default.
• W2145273349 hasConcept C2778594517 @default.
• W2145273349 hasConcept C2779384505 @default.
• W2145273349 hasConcept C2781059491 @default.
• W2145273349 hasConcept C2781413609 @default.
• W2145273349 hasConcept C535046627 @default.
• W2145273349 hasConcept C71924100 @default.
• W2145273349 hasConcept C87355193 @default.

• next